Aster DM Healthcare Limited — Q4 FY25 earnings call

Call held 21 May 2025

Management summary

Aster DM Healthcare delivered a strong full-year performance in FY25, characterized by significant margin expansion and strategic restructuring, including the GCC demerger and the announced QCIL merger. While Q4 revenue was temporarily dampened by seasonal factors (Ramadan) and management transitions in the Kerala cluster, the company maintained high profitability. Management is pivoting toward a high-growth India-focused strategy with aggressive bed expansion and a clear roadmap to 23-24% EBITDA margins.

Highlights

  • Full year FY25 revenue reached ₹4,138 crores, representing a 12% YoY growth.

  • Operating EBITDA grew by 30% to ₹806 crores, with margins expanding to 19.5% from 16.8% in FY24.

  • Normalized PAT (excluding NCI and one-offs) rose 49% to ₹357 crores.

  • ARPOB increased by 12% YoY, driven by a 6% improvement in Average Length of Stay (ALOS).

  • Total bed capacity stood at 5,159 beds as of March 31, 2025, with a pipeline of 2,100+ additional beds.

  • The merger with Quality Care India Limited (QCIL) is on track for completion by Q4 FY26, creating a top-3 Indian hospital network with 10,300+ beds.

  • Promoter pledge successfully reduced from 99% to 41% following debt refinancing.

  • Q4 FY25 revenue growth was a modest 2% YoY at ₹1,000 crores, impacted by Ramadan and a strategic exit from wholesale pharmacy segments.

Key financials

  1. Revenue ₹4,138 Cr +12%YoY
  2. Operating EBITDA ₹806 Cr +30%YoY
  3. EBITDA Margin 19.5%
  4. Normalized PAT ₹357 Cr +49%YoY
  5. ARPOB Growth 12% +12%YoY
  6. Bed Count 5,159 beds

What they filed

Q1 FY27: revenue up 21.6%, net profit down 69.1% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue1,086 1,050 1,000 1,078 1,197 +10%1,186 +13%1,182 +18%1,311 +22%
EBITDA217 186 182 202 236 +9%202 +9%224 +23%256 +27%
Net profit106 64 86 94 121 +14%59 −8%154 +79%29 −69%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

SegmentEBITDA MarginRevenue
Kerala Cluster23.4%₹2,108 Cr
Karnataka & Maharashtra Cluster28.8%₹1,408 Cr
Andhra & Telangana Cluster12.7%₹473 Cr
Diagnostics (Labs)8%—

Guidance & targets

Margin

  • Group EBITDA Margin Margin · next 3-4 years · High confidence 23-24%
    we are also aiming to reach 23-24% in next 3-4 years’ timeline. So, we are very much committed in this regard.

    — Sunil Kumar, CFO

Volume

  • Inpatient Volume Growth Volume · FY26 · High confidence 7-8%
    Now volumes is something which we are very, very confident that will continue to grow at around 7-8% going forward.

    — Sunil Kumar, CFO

Revenue

  • ARPOB Growth Revenue · FY26 · Medium confidence 7-8%
    When we say that we grown at mid-teens, at least 7-8% will be with volumes and balance 7-8% will come from the ARPOB.

    — Sunil Kumar, CFO

Capacity

  • India Bed Expansion Capacity · next 3-4 years · High confidence 2,100+
    We are significantly strengthening our presence in South India through strategic capacity expansion of the 2,100 plus beds year mark for India expansion.

    — Alisha Moopen, Deputy Managing Director

Capex

  • Expansion Funding Capex · next 3-4 years · High confidence ₹1,500 crores
    So, balance INR 1,500 crores, which we need to spend over a period of next three to four years, right? And from the pre-IndAS or post-IndAS of view, my cash flow from operations, it's approximately 78% to 80%.

    — Sunil Kumar, CFO

Other

  • Non-Aster Lab Business Mix Other · FY26 · Medium confidence 36-38%

    Previously 28% → 36-38%

    So we look at somewhere between 36 to 38% is the non-Aster business which we want to drive in the labs.

    — Sunil Kumar, CFO

Risks & concerns

  • Kerala Cluster Management Transition

    medium

    Recent leadership changes at the flagship Medcity unit caused temporary operational friction.

    Both acknowledged

  • Receivables Risk in International Markets

    medium

    Maldives government change has increased pressure on payments, leading Aster to consciously reduce business volumes there to control DSO.

    Management acknowledged

  • Competitive Intensity in Key Markets

    medium

    Management maintains they are 'price leaders' and will not engage in discount-based strategies despite rising competition in Kerala and Bangalore.

    Analyst downplayed

  • Project Execution Delays

    low

    Several brownfield expansions (Bangalore, Ongole, Medcity) have seen 3-4 month delays due to project team changes.

    Analyst acknowledged

Areas of evasion (2)

  • Specific breakdown of QCIL debt levels (deferred to later)
  • Exact timeline for the Hyderabad Women and Child hospital beyond '2027'

Q&A highlights

3 direct
Kerala Cluster Performance and Occupancy Dip Direct
We believe that almost 2.5%-3% of the revenue hit has been caused because of the Ramadan impact... we expect that in the next quarter and two, things should kind of move back to start seeing the growth.

Explains the temporary slowdown in the company's largest cluster and sets expectations for a recovery in H1 FY26.

Asked by Amey Chalke

Sustainability of 19% EBITDA Margins Direct
These numbers what we published is more of a sustainable... we are also aiming to reach 23-24% in next 3-4 years’ timeline. So, we are very much committed in this regard.

Confirms that recent margin improvements are structural and provides a long-term target that includes merger synergies.

Asked by Kunal Randeria

QCIL (Care Hospitals) Turnaround in Hyderabad Direct
Hyderabad, we currently run five hospitals, and of which two hospitals have needed significant help... we've renovated Banjara... a significant turnaround is underway.

Addresses the underperformance of the Care Hospitals' Hyderabad cluster, which is a key part of the upcoming merger.

Asked by Amey Chalke

2 min read 5 chapters

Detailed narrative

Restructuring and Merger Synergies

Aster DM is undergoing a massive transformation, having completed the GCC demerger and now moving toward a merger with Blackstone-backed Quality Care India Limited (QCIL). The combined entity will be a healthcare powerhouse with over 10,300 beds and pro-forma FY25 revenue of ₹8,105 crores. Management expects significant synergies in procurement and supply chain optimization, targeting an additional 100 basis points in margin improvement from scale alone. The merger is currently awaiting final NCLT and stock exchange approvals, with a target completion date in Q4 FY26.

Kerala Cluster: Navigating Short-term Headwinds

The Kerala cluster, Aster's largest, faced a challenging Q4 with revenue growth of only 5% and a 6% decline in IPD volumes. Management attributed this to a full month of Ramadan impacting local footfalls and Medical Value Travel (MVT) from Maldives and Oman. Additionally, a leadership transition at the flagship Medcity unit caused some operational friction. However, the cluster maintained a healthy 23.4% EBITDA margin for the full year, and management expects a return to 'mid-teens' growth as new leadership settles in and 200 new beds are operationalized.

Aggressive Expansion in South India

The company has a clear roadmap to add 2,100+ beds in India over the next 3-4 years. In Bangalore, Aster aims to exceed 2,000 beds, positioning itself among the top three providers in the city. Key projects include a new 430-bed hospital on Sarjapur Road and expansions at Aster Whitefield and CMI. In Kerala, 818 beds will be added, including greenfield projects in Kasargod and Trivandrum. This expansion will be funded primarily through internal accruals and existing cash reserves, as the company currently operates in a net cash position of ₹739 crores.

Operational Efficiency and Margin Roadmap

A central theme of the call was the structural improvement in EBITDA margins, which rose from 16.8% to 19.5% in FY25. This was driven by a 440 bps reduction in material costs (excluding wholesale pharmacy) since FY20 and a 70 bps improvement in manpower efficiency. Management has set a bold target of 23-24% margins within 3-4 years. Key levers include doubling volumes to gain procurement leverage, consolidating fragmented overheads like insurance and AMCs, and commissioning 30-32 MW of captive solar power plants to reduce energy costs.

Diagnostics and Pharmacy: Pivoting to Profitability

Aster's lab business achieved a significant turnaround, moving from a negative EBITDA of ₹9 crore in FY24 to a positive ₹10 crore in FY25. The strategy is to increase the share of non-Aster (B2C/external B2B) business from the current 28% to 36-38% to drive higher margins. In the pharmacy segment, the company strategically exited loss-making wholesale segments, which artificially suppressed Q4 revenue growth but is expected to restore segment profitability by Q1 FY26. The retail pharmacy network now stands at 203 branded stores.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls